Table 3 Summary of major bispecific antibodies in R/R DLBCLs and NHLs
Medicine name | Targets | Mode of administration | Study | Patients | Treatment | Responses |
|---|---|---|---|---|---|---|
Blinatumomab | CD19/CD3ε, IgG1 | IV | NCT00274742 Phase I | R/R DLBCL | Monotherapy (60 μg/m2/day) | ORR/CRR, 54.6% (6/11)/36.4% (4/11) |
NCT01741792 Phase II | R/R DLBCL | Monotherapy (evaluated stepwise or flat dosing) | ORR/CRR, 42.9% (9/21)/19% (4/21) | |||
NCT02910063 Phase II/III | R/R DLBCL | Monotherapy (stepwise) | ORR/CRR, 37% (15/41)/ 22% (9/41) | |||
Mosunetuzumab | CD20/CD3δε, IgG1 | IV or SC | NCT02500407 Phase I/Ib | R/R DLBCL | Monotherapy (dose escalation and standard 3 + 3 escalation) | ORR/CRR, 33% (13/39)/ 21% (8/39) |
NCT02500407 Phase I | R/R B-NHL | Monotherapy (dose escalation) | Aggressive NHL, ORR/CRR, 34.9% (45/129)/19.4% (25/129) Post CAR-T, ORR/CRR, 36.8% (7/19)/26.3% (5/19) | |||
NCT03677141Phase Ib/II | R/R NHL | M-CHOP (step-up dosing) | ORR/CRR, 86% (6/7)/71% (5/7) | |||
Epcoritamab | CD20/CD3ε, IgG1 | SC | NCT03625037 Phase I/II | R/R DLBCL | Monotherapy | 12-60 mg, ORR/CRR, 68% (15/22)/45% (10/22) 48 mg, ORR/CRR, 88% (7/8)/38% (3/7) 60 mg, ORR/CRR, 100% (3/3)/100% (3/3) |
NCT03625037 EPCORE NHL-1 | R/R DLBCL | Monotherapy (QW, cycle 1–3; Q2W, cycle 4–9; Q4W, cycle ≥ 10) | ORR/CRR, 63% (99/157)/39% (61/157) CAR-T naïve, ORR/CRR, 69% (66/96)/42% (40/96) Post CAR-T, ORR/CRR, 54% (33/61)/34% (21/61) | |||
Glofitamab | CD20/CD3ε (2:1), IgG1 | IV | NCT03075696 Phase I | R/R DLBCL | Monotherapy (dose escalation, and dose expansion), Gpt pretreatment | ORR/CRR, 41.4% (30/73)/28.8% (21/73) |
NCT03533283 Phase I/II trial | R/R DLBCL | Glofitamab + Pola (step-up dosing for Glofitamab), Gpt pretreatment | ORR/CRR, 73% (24/33)/51.5% (17/33) | |||
NCT03075696 Phase II | R/R DLBCL | Monotherapy (step-up dosing), Gpt pretreatment | ORR/CRR, 51.6 (80/155)/39.4% (61/155) | |||
NCT03467373 Phase Ib | R/R NHL | Glofitamab + R-CHOP, (step-up dosing began in cycle 2 for Glofitamab), Gpt pretreatment | ORR/CRR, 90% (28/31)/77% (24/31) | |||
Odronextamab | CD20/CD3δε, IgG4 | IV | NCT02290951 Phase I | R/R DLBCL | Monotherapy (step-up dosing) | CAR-T naïve (All dose), ORR/CRR, 42.6% (23/53)/29.6% (16/54) Post CAR-T (All dose), ORR/CR, 31.1% (14/45)/22.2% (10/45) |
Plamotamab | CD20/CD3δε, IgG1 |  | NCT02924402 Phase I | R/R DLBCL | Monotherapy (dose-escalation) | All patients, ORR/CRR, 47.4% (9/19)/26.3% (5/19) Post CAR-T, ORR/CRR, 46.2% (6/13)/30.8% (4/13) |